SCHEMBL10249958

SCHEMBL10249958

CNCC1Cc2ccc(CNS(=O)(=O)CC3CC3)cc2C1Cc1cccc(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 8/20 0.46
KCNH2 Q12809 2/20 0.36
CARM1 Q86X55 2/20 0.35
PRMT6 Q96LA8 2/20 0.35
CXCR4 P61073 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
GAK O14976 1/20 0.33
STK16 O75716 1/20 0.33
AAK1 Q2M2I8 1/20 0.33
CDKL2 Q92772 1/20 0.33
BMP2K Q9NSY1 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
TP53 P04637 1/20 0.33
CNR1 P21554 1/20 0.33
CXCR3 P49682 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL617107 0.93 SLC6A9 (0.45) SLC6A9KCNH2TAAR1
SCHEMBL616145 0.90 SLC6A9 (0.56) SLC6A9KCNH2GAKSTK16AAK1
SCHEMBL616078 0.89 SLC6A9 (0.46) SLC6A9KCNH2CARM1PRMT6GAK
SCHEMBL604193 0.89 SLC6A9 (0.54) SLC6A9KCNH2CARM1PRMT6SLC6A2
SCHEMBL617452 0.87 SLC6A9 (0.38) SLC6A9KCNH2CARM1PRMT6CXCR4
SCHEMBL615918 0.87 GALR3 (0.44) SLC6A9KCNH2CARM1PRMT6SLC6A2
SCHEMBL616265 0.86 SLC6A9 (0.41) SLC6A9CARM1PRMT6CXCR4SLC6A2
SCHEMBL617025 0.86 SLC6A9 (0.62) SLC6A9KCNH2
SCHEMBL614760 0.85 SLC6A9 (0.44) SLC6A9KCNH2CARM1PRMT6CXCR4
SCHEMBL616725 0.82 SLC6A9 (0.54) SLC6A9KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051280-B2 Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy AbbVie Deutschland GmbH & Co. KG (DE) 2015-06-09 US disclosed
US-8883839-B2 Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy ABBOTT LABORATORIES (US) 2014-11-11 US disclosed
US-8883839-B2 Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy ABBOTT LABORATORIES (US) 2014-11-11 US disclosed
US-20120295881-A1 TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBOTT GMBH & CO. KG (DE) 2012-11-22 US disclosed
WO-2012020133-A1 TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBOTT GMBH & CO. KG (DE) 2012-02-16 WO disclosed
US-20120040947-A1 TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBOTT LABORATORIES (US) 2012-02-16 US disclosed
US-20120040947-A1 TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBOTT LABORATORIES (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040947-A1 TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY SLC10A1, SUGT1, SLC10A2 SLC6A9 42/4885KCNH2 1552/4885CARM1 1742/4885
US-20120295881-A1 TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY SLC10A1, SUGT1, SLC10A2 SLC6A9 42/4885KCNH2 1552/4885CARM1 1742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.